Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography
- PMID: 11294518
- DOI: 10.1097/00007691-200104000-00012
Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography
Abstract
Recipients of organ transplants remain particularly dependent on prednisolone as part of their maintenance immunosuppression. Despite this, the pharmacokinetics of prednisolone have never been fully characterized in these patients, and consequently dosing remains empirical. Accurate monitoring of prednisolone, its primary metabolite prednisone, and endogenous cortisol suppression in such patients may provide a means of improving the clinical outcome by adjusting for variability in prednisolone pharmacokinetics and pharmacodynamics. Measurement of endogenous cortisol may provide an independent marker of prednisolone pharmacodynamics. A simple isocratic reverse-phase high-performance liquid chromatography procedure, using betamethasone as an internal standard, was developed to quantify plasma prednisolone, prednisone, and cortisol simultaneously. The steroids were extracted from 0.5 mL plasma with 3 mL (1:1 v/v) ethyl acetate/tert-methyl butyl ether and 0.1 mL phosphoric acid, washed in 0.1 mol/L NaOH before a final drying step and reconstitution in mobile phase for injection. Separation was achieved using a Supelcosil LC-18-DB, 150 x 4.6-mm, 5-microm particle size, reverse-phase column attached to a Newguard 15 x 3-mm, RP8 guard column maintained at 25 degreesC, with ultraviolet detector set at 254 nm. The mobile phase consisted of 16% isopropanol in water containing 0.1% trifluoroacetic acid, set at a flow rate of 1.2 mL/min. The assay was linear up to 1,002 microg/L for prednisolone, 982 microg/L for prednisone, and 545 microg/L for cortisol. Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol. Intra-assay inaccuracy was <7% of nominal values for prednisolone, prednisone, and cortisol. The lower limit of quantification was 7 microg/L for prednisolone and prednisone and 10 microg/L for cortisol. Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively. The authors describe a robust, inexpensive, and simple method suitable for therapeutic drug monitoring or pharmacokinetic studies of prednisolone; it may also be used to measure the suppression of endogenous cortisol production.
Similar articles
-
Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography-tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 1;859(1):42-51. doi: 10.1016/j.jchromb.2007.09.003. Epub 2007 Sep 14. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17928278
-
Simultaneous liquid-chromatographic determination of prednisone and prednisolone in plasma.Clin Chem. 1988 Sep;34(9):1897-9. Clin Chem. 1988. PMID: 3416442
-
Simultaneous determination of deflazacort metabolites II and III, cortisol, cortisone, prednisolone and prednisone in human serum by reversed-phase high-performance liquid chromatography.J Chromatogr B Biomed Appl. 1994 Aug 5;658(1):55-61. doi: 10.1016/0378-4347(94)00193-6. J Chromatogr B Biomed Appl. 1994. PMID: 7952132
-
Simultaneous measurement of prednisone, prednisolone and hydrocortisone in plasma by high performance liquid chromatography.Ann Biol Clin (Paris). 1990;48(2):87-90. Ann Biol Clin (Paris). 1990. PMID: 2344076
-
What do we know about steroids metabolism and 'PK/PD approach' in AKI and CKD especially while on RRT--current status in 2014.Blood Purif. 2014;38(2):154-7. doi: 10.1159/000368390. Epub 2014 Nov 29. Blood Purif. 2014. PMID: 25471548 Review.
Cited by
-
Bioavailability effect of methylprednisolone by polymeric micelles.Pharm Res. 2008 Jan;25(1):39-47. doi: 10.1007/s11095-007-9484-0. Epub 2007 Nov 8. Pharm Res. 2008. PMID: 17990084
-
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.Clin Pharmacokinet. 2009;48(8):489-516. doi: 10.2165/11317240-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19705921 Review.
-
Novel environmental and sustainable approach for concurrent assay of antineoplastics in VMP regimen with a comprehensive Pharmacokinetic study.Sci Rep. 2025 Aug 14;15(1):29894. doi: 10.1038/s41598-025-15078-6. Sci Rep. 2025. PMID: 40813403 Free PMC article.
-
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.Clin Pharmacokinet. 2009;48(7):419-62. doi: 10.2165/11317230-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19691367 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous